stockrow
Friday 6 November 2026
Export BIOA’s income statement to Excel — free account
BioAge Labs, Inc.
BIOA Healthcare Drug Manufacturers Specialty & Generic
BioAge Labs, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million.
- Revenue
- −85.5%
- EPS
- −30.4%
- Free cash flow
- −92.8%
- Total debt
- −83.6%
Quarter to September 2026, against a year earlier
5.30
0.24
−4.33%
Follow BIOA
Alert me
BioAge Labs, Inc. (BIOA) P/E ratio
BioAge Labs, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 3 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| EBS Emergent Biosolutions Inc. compare | n/m |
| SIGA Siga Technologies Inc. compare | n/m |
| ADCT ADC Therapeutics SA compare | n/m |
| ACB Aurora Cannabis Inc. compare | n/m |
| BIOA BioAge Labs, Inc. | n/m |
| GLAS Glass House Brands Inc. compare | n/m |
| ANIK Anika Therapeutics Inc. compare | n/m |
| CGC Canopy Growth Corporation compare | n/m |
| LFCR Lifecore Biomedical, Inc. compare | n/m |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)